Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
crawled date : 2021 - 10 - 21 source : Www.biospace.com save search
Newly Published Data Continue to Support Long-Term Efficacy of TEPEZZA® (teprotumumab-trbw) for Thyroid Eye Disease (TED)
Published: 2021-10-21 (Crawled : 19:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.29%
H: 2.43%
C: 2.13%
disease eye eye disease
Cue Biopharma Announces Publication in The Journal of Clinical Investigation Highlighting Immuno-STAT Biologics for the Treatment of Chronic Infectious Diseases
Published: 2021-10-21 (Crawled : 18:00) - biospace.com/
CUE | $1.55 -1.9% 69K
|
Health Technology
|
| O: -0.24%
H: 2.51%
C: -0.97%
disease treatment biopharma infectious disease
Universities and DENSO Develop Biosensor to Detect SARS-CoV-2 and Accelerate Development for practical application
Published: 2021-10-21 (Crawled : 18:00) - biospace.com/
DNZOY | $18.47 47K
|
Manufacturing
|
| O: -1.31%
H: 2.0%
C: 0.6%
sensor application sars-cov-2
Taysha Gene Therapies to Participate in Upcoming Gene Therapy Summit
Published: 2021-10-21 (Crawled : 17:00) - biospace.com/
TSHA | $2.34 -2.91% 340K
|
Health Technology
|
| O: 0.12%
H: 1.74%
C: -3.45%
gene therapies gene therapy therapy
Adagene to Participate in the Jefferies Virtual China Biotech Summit
Published: 2021-10-21 (Crawled : 17:00) - biospace.com/
ADAG | $2.64 1.8K
|
Manufacturing
| Email alert
Add to watchlist
biotech china iot
Cocrystal Pharma to Present Data from its Oral and Intranasal COVID-19 Therapeutics Programs at the World Antiviral Congress 2021
Published: 2021-10-21 (Crawled : 17:00) - biospace.com/
COCP | $1.495 5.2K
|
Health Technology
|
| O: 3.23%
H: 4.17%
C: 1.13%
covid antiviral pharma
Sio Gene Therapies Announces Granting of FDA Fast Track Designation for Investigational AXO-AAV-GM1 (AAV9-GLB1) Gene Therapy in Patients with GM1 Gangliosidosis
Published: 2021-10-21 (Crawled : 17:00) - biospace.com/
SIOX | $0.478 -20.5% 40K
|
Health Technology
|
| O: 9.3%
H: 12.98%
C: 0.43%
fda fda fast track gene therapies fast track gene therapy therapy aav9 fast track designation designation
Atreca Enters into Licensing Agreement with Bill & Melinda Gates Medical Research Institute to Develop a Monoclonal Antibody for the Prevention of Malaria
Published: 2021-10-21 (Crawled : 17:00) - biospace.com/
BCEL P | $0.0761 350K
|
Health Technology
|
| O: 1.15%
H: 4.72%
C: -0.19%
antibody research license malaria
FDA Signs Off on Moderna, J&J Boosters and Mixed Doses
Published: 2021-10-21 (Crawled : 15:15) - biospace.com/
JNJ | News | $147.17 0.98% 3.2M
|
Health Technology
|
| O: 0.32%
H: 0.05%
C: -0.55%
fda
Personalis to Announce Third Quarter Financial Results on November 4, 2021
Published: 2021-10-21 (Crawled : 15:00) - biospace.com/
PSNL | $1.28 5.79% 130K
|
Health Technology
|
| O: 0.41%
H: 0.71%
C: -1.17%
financial results results
Austin L. Chiang, M.D., M.P.H. joins Medtronic as Chief Medical Officer for Gastrointestinal business
Published: 2021-10-21 (Crawled : 15:00) - biospace.com/
MDT | $79.255 0.08% 2.6M
|
Health Technology
|
| O: 0.12%
H: 0.07%
C: -0.24%
test gastrointestinal
Dynavax to Report Third Quarter 2021 Financial Results and Host Conference Call on November 4, 2021
Published: 2021-10-21 (Crawled : 14:00) - biospace.com/
DVAX | $11.57 2.03% 1M
|
Health Technology
|
| O: 1.7%
H: 2.43%
C: 1.67%
financial results results conference
Agilent PD-L1 IHC 28-8 pharmDx Receives CE-IVD Mark as a Companion Diagnostic Test in Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Published: 2021-10-21 (Crawled : 14:00) - biospace.com/
A | $132.86 0.32% 620K
|
Health Technology
|
| O: 0.08%
H: 0.2%
C: -0.49%
test diagnostic
Lucid Diagnostics Appoints Suman Verma MD, PhD as Chief Scientific Officer
Published: 2021-10-21 (Crawled : 14:00) - biospace.com/
LUCD | $0.7937 -0.66% 97K
|
|
| O: 0.73%
H: 11.98%
C: 11.98%
PAVM | $1.95 12K
|
Health Technology
|
| O: 0.0%
H: 5.14%
C: 2.32%
diagnostics diagnostic lucid-ms
ALX Oncology Announces First Patient Dosed in ASPEN-05, a Phase 1/2 Study of Evorpacept in Combination with Venetoclax and Azacitidine in Patients with Acute Myeloid LeukemiaSecond study of evorpacept in patients with myeloid malignancies
Published: 2021-10-21 (Crawled : 14:00) - biospace.com/
ALXO M | $15.71 -0.19% 210K
|
Commercial Services
|
| O: -0.2%
H: 2.32%
C: -1.72%
myeloid leukemia phase 1 leukemia
Ligand and CR Double-Crane Enter Collaboration Agreement to Develop an Oral COVID-19 Therapeutic Using Ligand’s BEPro Technology™
Published: 2021-10-21 (Crawled : 14:00) - biospace.com/
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: -0.08%
H: 0.41%
C: 0.41%
LGND | $72.33 -0.26% 45K
|
Health Technology
|
| O: -0.17%
H: 1.8%
C: 0.91%
covid collaboration technology
LogicBio Therapeutics Announces Successful Repopulation of Diseased Livers in Mice with Healthy Corrected Hepatocytes in Two New Indications Using GeneRide™ Genome Editing Technology
Published: 2021-10-21 (Crawled : 13:15) - biospace.com/
LOGC | $2.07 -0.48%
|
Health Technology
|
| O: 5.2%
H: 0.0%
C: -8.24%
disease genome editing technology liver
iSpecimen® to Report Third Quarter 2021 Results on November 4, 2021
Published: 2021-10-21 (Crawled : 13:15) - biospace.com/
ISPC | $0.3024 -28.17% 2.3M
|
Professional, Scientific, and T...
|
| O: 0.13%
H: 1.46%
C: 0.67%
results
Selecta Biosciences and Genovis Enter Exclusive License Agreement to Advance Next-Generation IgG Protease in Gene Therapy and Autoimmune Disease
Published: 2021-10-21 (Crawled : 13:15) - biospace.com/
SELB 4 | $0.8812 -8.0% 2.12% 0
|
Health Technology
|
| O: 0.0%
H: 4.37%
C: 1.54%
disease gene therapy therapy license
Obsidian Therapeutics Appoints Maria Fardis, Ph.D., to Board of Directors
Published: 2021-10-21 (Crawled : 13:15) - biospace.com/
GILD | News | $66.33 0.26% 2.8M
|
Health Technology
|
| O: 0.34%
H: 0.15%
C: -0.15%
therapeutics
Gainers vs Losers
| 72% | 28% |
Top 10 Gainers
AGBA | News | $1.27 217.5% 120M
|
Finance
EGOX | $0.054 50.0% 290M
|
RWOD | $10.52 31.56% 5.9M
|
n/a
ZCMD | $1.905 31.38% 30M
|
Commercial Services
NVFY | $2.71 28.44% 31M
|
Consumer Durables
MRDB 4 | $0.536 27.65% 2M
|
n/a
BSFC | $0.0822 27.64% 75M
|
Manufacturing
TPET | $0.4121 25.68% 45M
|
n/a
INDO | $5.1 25.0% 15M
|
Energy Minerals
CHRO | $1.53 24.9% 100K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.